Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

Status unconfirmed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.

Key facts

Study ID

NCT00083083

Run by

American College of Radiology Imaging Network

People needed

250

Starts

2005-03-01

Last updated by the study team

2011-03-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham — Birmingham, Alabama, United States
• Scottsdale Medical Imaging, Limited — Scottsdale, Arizona, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• Radiological Associates of Sacramento Medical Group at Sutter Cancer Center — Sacramento, California, United States
• Hospital of Saint Raphael — New Haven, Connecticut, United States
• Bethesda Comprehensive Cancer Care Center at Bethesda Memorial Hospital — Boynton Beach, Florida, United States
• North Broward Medical Center — Dearfield Beach, Florida, United States
• Integrated Community Oncology Network at Baptist Cancer Institute — Jacksonville, Florida, United States
• Tallahassee Memorial Hospital — Tallahassee, Florida, United States
• Rush Cancer Institute at Rush University Medical Center — Chicago, Illinois, United States
• Saint John's Cancer Center at Saint John's Medical Center — Anderson, Indiana, United States
• Center for Cancer Care at Goshen General Hospital — Goshen, Indiana, United States
• CCOP - Northern Indiana CR Consortium — South Bend, Indiana, United States
• Greenebaum Cancer Center at University of Maryland Medical Center — Baltimore, Maryland, United States
• Dana-Farber Partners Cancer Care — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• South Shore Hospital — South Weymouth, Massachusetts, United States
• Josephine Ford Cancer Center at Henry Ford Hospital — Detroit, Michigan, United States
• West Michigan Cancer Center — Kalamazoo, Michigan, United States
• William Beaumont Hospital - Royal Oak Campus — Royal Oak, Michigan, United States
• Mallinckrodt Institute of Radiology at Washington University Medical Center — St Louis, Missouri, United States
• Renown Institute for Cancer at Renown Regional Medical Center — Reno, Nevada, United States
• Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Sister Patricia Lynch Regional Cancer Center at Holy Name Hospital — Teaneck, New Jersey, United States
• J. Phillip Citta Regional Cancer Center at Community Medical Center — Toms River, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.